PCV4: THE EFFECT OF STATIN DOSE ON ATTAINMENT OF TARGET LDL-C LEVELS  by Al-Zakwani, IS et al.
307Abstracts
OBJECTIVES: Poor adherence to antihypertensive regi-
mens has frequently been cited as a factor for failing to
achieve blood pressure goals in patients with hyperten-
sion. The objective of our study was to determine factors
associated with adherence to antihypertensive regimens in
members enrolled in a commercial managed care organi-
zation (MCO). METHODS: All members evaluated 
had a diagnosis of hypertension and were continuously
enrolled during the one-year study period. Severity of
illness was stratiﬁed by co-existing medical complications
associated with hypertension. Members receiving one or
more antihypertensive medications were the population
evaluated in our retrospective analysis. Average medica-
tion possession ratio (MPR) on all antihypertensive med-
ications was used as the primary adherence indicator in
this study. Factors evaluated included member age,
gender, severity of illness, number of concurrent antihy-
pertensive medications, dosing schedule, and sum of total
days supply of medication. Variable were evaluated using
a forward step-wise regression analysis. RESULTS: There
were 3306 members identiﬁed with hypertension in 
the MCO. MPR was evaluated in 2116 members on an-
tihypertensive medications. The mean age was 52.2 years
and 47% were female. The most common classes of anti-
hypertensive medications utilized were Calcium Channel
Blockers, ACE Inhibitors, and Diuretics. The regression
model for average MPR was signiﬁcant (F = 127.72, 
p < 0.001). Factors signiﬁcantly correlated with average
MPR were total days supply (b = 0.73, p < 0.001), age
(b = 0.08, p < 0.001), number of current medications 
(b = -.057, p < 0.001) and dosing schedule (b = 0.08, 
p < 0.001). CONCLUSIONS: A number of factors were
found to be signiﬁcant predictors of adherence to antihy-
pertensive medications. Members that were older and
received the drugs for longer periods of time had better
adherence. Adherence to medication tended to decrease
as the number of concurrent medications increased and
as the number of doses of medication taken per day
increased. Disease severity and gender were not found to
be signiﬁcant predictors of adherence.
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OBJECTIVE: The objective of this study was to evaluate
the effects of various statin doses on the attainment of
target LDL-Cholesterol (LDL-C) levels in clinical prac-
tice. METHODS: Patients newly initiated on atorvas-
tatin, ﬂuvastatin, pravastatin, or simvastatin from 1/99 to
6/99 were retrospectively identiﬁed from a southeastern
U.S. health plan database. Exclusion criteria included
statin therapy in the prior 6 months, less than 90 days of
statin therapy, switching of statin, use of combination
dyslipidemia therapy, and less than 18 months of contin-
uous plan enrollment. For each statin dose, attainment 
of target LDL-C based on NCEP ATP II guidelines was 
analyzed using univariate (unadjusted) and multivariate
(adjusted) logistic regression. Covariates utilized in the
adjusted analysis were age, gender, presence of athero-
sclerotic vascular disease, and difference between baseline
and target LDL-C. RESULTS: A total of 1938 statin dose
episodes from 1645 eligible patients (mean age = 66.3 ±
10.4 years, 47% male) were evaluated. Mean absolute
(percent) LDL-C reductions across statin dose ranges
were: atorvastatin [67–81mg/dL (39–43%)], ﬂuvastatin
[34–42mg/dL (21–26%)], pravastatin [39–45mg/dL
(24–26%)], and simvastatin [52–67mg/dL (32–38%)]. In
the unadjusted results, atorvastatin 20mg, ﬂuvastatin 
20mg and 40mg, pravastatin 20mg and 40mg, and sim-
vastatin 10mg had signiﬁcantly lower odds of attaining
NCEP II LDL-C target when compared to atorvastatin 
10mg. In the adjusted results, ﬂuvastatin 20mg and 
40mg, pravastatin 20mg and 40mg, and simvastatin 
10mg and 20mg had signiﬁcantly lower odds of attain-
ing NCEP II LDL-C target as compared to atorvastatin
10mg. CONCLUSIONS: Patients prescribed atorvastatin
10mg had greater odds of attaining their target LDL-C
level than patients prescribed all other statin doses in the
adjusted analysis except for simvastatin 40mg and ator-
vastatin 20mg.
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OBJECTIVES: To examine the clinical effectiveness of
amlodipine as monotherapy or in combination with other
antihypertensives in systolic blood pressure (SBP) control
and JNC IV goal attainment within a multi-center ambu-
latory care setting. METHODS: Hypertensive adults were
identiﬁed over a 4-year period (1998–2001) from a large
commercially available electronic medical record (EMR)
database covering over 360,000 US primary care patients.
Study patients were required to have initiated therapy
with amlodipine and have at least one BP measurement
within 6 months prior to and 12 months following the
index date. Those with a documented diagnosis of CHF
or prior use of calcium channel blockers were excluded.
Mean change in SBP was compared using multivariable
regression, controlling for differences in age, gender,
comorbid conditions, baseline SBP, and days between
beginning and ending BP reading. Incremental rates of
JNC VI goal attainment are also presented. RESULTS:
One thousand one hundred seventy-ﬁve patients were
identiﬁed. Mean baseline SBP was 159.5mmHg (SD:
19.5). Adjusted SBP reductions in mmHg (%) were 16.0
